Internal Medicine, Medical Oncology · Mishawaka, IN
NPI
1558365031
Since 2005
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
5340 Holy Cross Pkwy
Mishawaka, IN, 46545
Phone (574) 237-1328
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.3M
100,994 services
Medicare patients, 2024
641
Average age 75
Drug cost, 2024
$7.0M
1,666 prescriptions
Company payments, 2025
$1,115
From 25 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jose A Bufill was code Q5125 (injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram), 14,280 times for 12 patients. In total Jose A Bufill billed 100,994 services in 145 codes, and Medicare paid $1.3M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-01-03.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| Q5125 Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram | Office | 14,280 | 12 | $0.41 | $5,795 |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 13,090 | 117 | $0.10 | $1,350 |
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 10,200 | 11 | $0.26 | $2,674 |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 6,040 | 12 | $2.23 | $13K |
| J0185 Injection, aprepitant, 1 mg | Office | 3,900 | 12 | $1.34 | $5,216 |
| J0897 Injection, denosumab, 1 mg | Office | 2,100 | 14 | $18.61 | $39K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,370 | 63 | $0.09 | $121 |
| 99214 Office E&M - Established | Office | 633 | 247 | $88.57 | $56K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 580 | 24 | $0.75 | $438 |
| 99213 Office E&M - Established | Office | 456 | 285 | $61.66 | $28K |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 384 | 21 | $0.07 | $27.63 |
| 96375 Injection Administration | Office | 296 | 71 | $10.97 | $3,247 |
| 96372 Injection Administration | Office | 246 | 74 | $10.31 | $2,537 |
| J9190 Injection, fluorouracil, 500 mg | Office | 231 | 13 | $2.46 | $568 |
| 93793 Care Management/Coordination | Office | 204 | 14 | $7.83 | $1,597 |
By year: 2022 $4.8M for 215,746 services; 2023 $2.7M for 161,690 services; 2024 $1.3M for 100,994 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jose A Bufill prescribed most often to Medicare patients was Pantoprazole Sodium, with 106 prescriptions and refills. In total Jose A Bufill wrote 1,666 Medicare prescriptions that cost $7.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Pantoprazole Sodium Generic | 106 | 219 | 33 | $2,137 |
| Anastrozole Generic | 81 | 217 | 26 | $1,236 |
| Warfarin Sodium Generic | 77 | 186 | 15 | $716 |
| Imbruvica Ibrutinib | 74 | 74 | Under 11 | $1.2M |
| Acyclovir Generic | 67 | 144 | 19 | $1,041 |
| Pomalyst Pomalidomide | 59 | 59 | Under 11 | $1.1M |
| Xarelto Rivaroxaban | 57 | 88 | 11 | $50K |
| Venclexta Venetoclax | 57 | 57 | Under 11 | $488K |
| Revlimid Lenalidomide | 51 | 51 | Under 11 | $983K |
| Eliquis Apixaban | 42 | 50 | Under 11 | $29K |
| Xtandi Enzalutamide | 42 | 42 | Under 11 | $582K |
| Bicalutamide Generic | 40 | 52 | Under 11 | $850 |
| Hydroxyurea Generic | 40 | 110 | 12 | $748 |
| Prochlorperazine Maleate Generic | 38 | 38 | 22 | $446 |
| Potassium Chloride Generic | 35 | 51 | 11 | $240 |
Brand drugs: 568 claims; generic drugs: 1,098 claims; opioid claims: 42.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jose A Bufill $1,115 ($1,115 in general payments such as food, travel and fees) from 25 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $176.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 5 | $176 |
| Janssen Biotech, Inc. JNJ | 1 | $148 |
| E.R. Squibb & Sons, L.L.C. BMY | 5 | $137 |
| Novartis Pharmaceuticals Corporation NVS | 4 | $102 |
| Pfizer Inc. PFE | 3 | $70.77 |
| Gilead Sciences, Inc. GILD | 2 | $42.52 |
| Array Biopharma Inc PFE | 1 | $32.05 |
| Syndax Pharmaceuticals, Inc. SNDX | 1 | $31.45 |
| Abbvie Inc. ABBV | 2 | $29.91 |
| Daiichi Sankyo Inc. 4568.T | 1 | $29.55 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.